A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Standard of Care

15849GS-US-563-5926OpenA Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Standard of CareNCT06630299IndustrialAdultTreatmentIIIOtherKumar, PrincyGeorgetown University Medical Center; Lombardi Comprehensive Cancer CenterGUMC Medicine Infectious Disease; GUMC PFS2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>